Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Versus TACE Plus SBRT in Liver Carcinoma
NCT03895359Phase 3Recruiting
- Start
- May 2019
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) and liver carcinoma (2 arms). Primary endpoints: Overall Survival at 2 years and Time to Intrahepatic Progression up to 2 years. Started May 2019; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)liver carcinoma
Beyond the preview
Go deeper on NCT03895359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895359.